Education
About Us
Working with TipRanks
Follow Us
BBP - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Products ETF (BBP)
Rating:61Neutral
Price Target:
$77.00
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid year-to-date returns, indicating strong recent performance.
Focus on High-Growth Sector
The fund is heavily concentrated in the health care sector, which often benefits from innovation and long-term growth trends.
Top Holdings Showing Positive Momentum
Several of the top holdings, such as Ionis Pharmaceuticals and Insmed, have shown strong year-to-date gains, supporting the ETF's overall performance.
Negative Factors
High Sector Concentration
Nearly all of the ETF's exposure is in the health care sector, making it vulnerable to sector-specific risks.
Limited Geographic Diversification
The ETF is almost entirely focused on U.S.-based companies, offering little protection against international market opportunities or risks.
Above-Average Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which can eat into investor returns over time.
BBP vs. SPDR S&P 500 ETF (SPY)
AUM30.97M
RegionNorth America
Expense Ratio0.79%
Beta0.95
IssuerVirtus
Inception DateDec 17, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedLifeSci Biotechnology Products Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,996
30 Day Avg. Volume3,647
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
109.70Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering55
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBP Summary
The Virtus LifeSci Biotech Products ETF (BBP) focuses on the biotechnology sector within health care, offering exposure to companies developing cutting-edge medical treatments and technologies. It follows the LifeSci Biotechnology Products Index and includes innovative firms like Ionis Pharmaceuticals and Crispr Therapeutics. This ETF could be appealing to investors looking for growth opportunities in the rapidly evolving biotech industry or those seeking to diversify their portfolio with health care-focused investments. However, new investors should be aware that the ETF’s performance is heavily tied to the biotech sector, which can be volatile and influenced by regulatory changes or scientific breakthroughs.
How much will it cost me?The Virtus LifeSci Biotech Products ETF (BBP) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like biotechnology that requires more research and expertise.
What would affect this ETF?The Virtus LifeSci Biotech Products ETF (BBP) could benefit from advancements in biotechnology and increased demand for innovative medical treatments, particularly in the U.S., where it is focused. However, it may face challenges from regulatory hurdles, high research and development costs, or broader economic downturns that could impact funding and growth in the biotech sector.
BBP Top 10 Holdings
The Virtus LifeSci Biotech Products ETF (BBP) is heavily concentrated in the U.S. biotechnology sector, showcasing a mix of established players and emerging innovators. Insmed is a standout, rising on strong clinical trial results and FDA approvals, though financial health remains a concern. Tarsus Pharmaceuticals is also gaining momentum thanks to strategic initiatives, but profitability challenges linger. On the flip side, Crispr Therapeutics is lagging, with bearish trends and unprofitability weighing on its performance. Overall, the fund’s focus on cutting-edge biotech offers growth potential but comes with the volatility typical of this high-risk, high-reward sector.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Travere Therapeutics | 3.44% | $1.07M | $3.17B | 107.02% | 55 Neutral | |
| Ionis Pharmaceuticals | 2.99% | $929.46K | $11.87B | 120.74% | 57 Neutral | |
| Insmed | 2.97% | $924.83K | $42.10B | 173.49% | 53 Neutral | |
| Aurinia Pharmaceuticals | 2.69% | $836.95K | $2.04B | 90.65% | 79 Outperform | |
| Madrigal Pharmaceuticals | 2.68% | $835.69K | $12.57B | 77.92% | 56 Neutral | |
| Tarsus Pharmaceuticals | 2.68% | $835.28K | $3.15B | 64.15% | 60 Neutral | |
| Ligand Pharma | 2.58% | $803.98K | $3.96B | 85.20% | 72 Outperform | |
| Roivant Sciences | 2.55% | $795.03K | $14.30B | 81.43% | 61 Neutral | |
| Theravance Biopharma | 2.49% | $774.44K | $914.13M | 86.39% | 60 Neutral | |
| United Therapeutics | 2.38% | $740.14K | $20.32B | 32.12% | 79 Outperform |
BBP Technical Analysis
Positive
―
Price Trends
72.28
Positive
68.23
Positive
63.29
Positive
Market Momentum
1.55
Negative
67.39
Neutral
80.99
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 74.72, equal to the 50-day MA of 72.28, and equal to the 200-day MA of 63.29, indicating a bullish trend. The MACD of 1.55 indicates Negative momentum. The RSI at 67.39 is Neutral, neither overbought nor oversold. The STOCH value of 80.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBP.
BBP Peer Comparison
Comparison Results
Performance Comparison
BBP
Virtus LifeSci Biotech Products ETF
78.00
16.13
26.07%
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
XHS
SPDR S&P Health Care Services ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents